by Raynovich Rod | Oct 1, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Stocks Hit New Highs Unfazed By Shutdown Biopharmaceutical stocks continued their blazing Q3 run today buoyed by assumptions that demand for pharmaceuticals will increase with 55 million new potential patients from Obamacare and that healthcare stocks are less...
by Raynovich Rod | Sep 26, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Will Not Wait for Congress-Huge Rally Across the Board Analysts and Media are Piling On-Momentum Rules IBB up 1.75% XBI up 1.81% Rayno Biopharmaceuticals stocks are in a new leg up with large cap winners: Alexion (ALXN $115) up 2% Cubist (CBST $67.62)...
by Raynovich Rod | Aug 28, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
But Uncertainty Clouds Intermediate Term Economic Outlook: Oil prices, Emerging Markets, Russia and the FED Concerns about another Middle East war and a spike in oil prices waned a bit today but many “undertoads” remain such as weak economic data, taper...
by Raynovich Rod | Aug 26, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Life science stocks resumed their upward trajectory today with major ETFs (FBT,IBB,XBI) up over 2% and a green screen for the sector. Mid-cap biopharma stocks are strong once again. The IBB hit an August low of $187 on August 19 after a high in early August near $201....
by Raynovich Rod | Aug 1, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech ETF (IBB) Hits New High of $200-Mid Caps Get Turbo Boost Positive Economic Data Helps The life science sector roared ahead again today helped by a 1% move in NASDAQ now at YTD highs up 21%. With an earlier post last week we urged “staying the...
by Raynovich Rod | Jul 18, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
7/19 11:45a EDT Update -Correction Limited to Techs, Biotechs Surge Tech correction continues with XLK down 1.5% but more money finding its way into biotech “bubblet” with IBB ($195) up 1.6%.Leading sectors are energy, healthcare and industrial with...
by Raynovich Rod | Jul 2, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotechnology Sector (IBB 178) Up Over 30% YTD Many Rayno Focus Stocks Outperformed the Market NASDAQ 3431 , S&P 1615 Biopharmaceutical-Top 5 Stocks- % Up YTD Albany Molecular (AMRI) 140.7 Alkermes (ALKS) 59.3 Astex (ASTX) up 49.5 Biogen Idec (BIIB) up 48.9...
by Raynovich Rod | Jun 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years...
by Raynovich Rod | Jun 3, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Biopharmaceuticals
Raise More Cash- No Change in Rayno Biopharma Portfolio Last month we raised the yellow flag on the biotech sector because of a choppy tape, new highs with weakness in MO (Momentum) plays and the anticipation of ASCO news that could trigger a “sell on the...
by Raynovich Rod | May 21, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Biopharmaceutical Stocks Rally- Many Rayno Picks up 2%+ If the past four days was the long awaited biotechnology correction it was barely noticeable, a mere 3.7% high to low over the past week.Today the rally has resumed with major large cap holdings from funds and...
